Monopar Therapeutics filed the paperwork for its IPO on 8/15/2019. The company will raise up to $40 Million. Monopar is a clinical stage biopharmaceutical company. The company will trade on NASDAQ under the symbol, “MNPR.”
Monopar’s lead candidate, Validive, is intended to treat oral mucositis in patients undergoing chemoradiotherapy treatment for head and neck cancer. The vast majority of patients undergoing chemoradiotherapy for head and neck cancer develop significant oral mucositis. Validive is delivered in a mucobuccal tablet (“MBT”) formulation for clonidine that allows for prolonged and enhanced local delivery of drug in the regions of mucosal radiation damage. The company plans to begin Ph III trials in the fourth quarter of 2019.
Monopar’s pipeline also includes: camsirubicin, is a novel analog of doxorubicin, and MNPR-101, a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor.
The company plans to use the proceeds of the offering to advance Validive into Ph III trials, and to continue to develop camsirubicin and MNPR-101.